China & China — National Medical Products Administration
8 shared events · Importance 8 · Last updated Jun 12, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Tech
China: China's China — National Medical Products Administration approved the IND application for ATG-201, facilitating the initiation of Phase I clinical trials within the country.
China — National Medical Products Administration: The China — National Medical Products Administration approved the IND application for ATG-201, enabling Antengene to proceed with Phase I clinical trials in China.
Jun 10, 2026 · 8 articles
Business
China: China, through its China — National Medical Products Administration (NMPA), is the regulatory authority that accepted the IND application for HBM7004, facilitating its potential clinical development within the country.
China — National Medical Products Administration: The China — National Medical Products Administration (NMPA) of China accepted the Investigational New Drug (IND) application for HBM7004, allowing Harbour BioMed to advance its drug towards clinical evaluation in China.
Jun 10, 2026 · 7 articles
Business
China: China is the country where the China — National Medical Products Administration operates and where Gumokimab has been approved for market, impacting its healthcare sector and patient population.
China — National Medical Products Administration: The China — National Medical Products Administration approved Gumokimab, enabling its commercialization in China and providing a new treatment option for patients with moderate-to-severe plaque psoriasis.
Jun 12, 2026 · 7 articles
Tech
China: China is the location where the initial PoC clinical study for IBI363 was conducted and where Innovent Biologics is based. The China NMPA has also granted Breakthrough Therapy Designations for IBI363.
China — National Medical Products Administration: The China — National Medical Products Administration (NMPA) of China has granted three Breakthrough Therapy Designations to IBI363, recognizing its potential for significant clinical advantage over existing therapies.
May 21, 2026 · 9 articles
Tech
China: China is relevant as the country where golidocitinib received approval from the China — National Medical Products Administration (NMPA).
China — National Medical Products Administration: The China — National Medical Products Administration (NMPA) of China approved golidocitinib in June 2024 for r/r PTCL, indicating regulatory progress for one of Dizal Pharmaceutical's key assets.
May 31, 2026 · 6 articles
Tech
China: Sac-TMT has multiple indications approved and marketed in China, with two included in the National Reimbursement Drug List, benefiting patients in the country.
China — National Medical Products Administration: The agency has granted sac-TMT six Breakthrough Therapy Designations and accepted a new indication application for review, indicating regulatory recognition of the drug's potential.
May 30, 2026 · 14 articles
Business
China: CardioACC, one of the companies Medtronic invested in, is based in Shenzhen, China, and received approval for its ICE system from the China — National Medical Products Administration.
China — National Medical Products Administration: The China — National Medical Products Administration approved CardioACC's ICE system in 2025, indicating regulatory acceptance of the technology.
Jun 03, 2026 · 6 articles
NEWSDESK
Explore this relationship live
Track how China and China — National Medical Products Administration interact across events, view sentiment trends, and discover connected entities.
Open Dashboard